Skip to content
Peptigraph home

Sermorelin vs Tirzepatide: What the Research Shows

Sermorelin and Tirzepatide side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[18]Growth hormoneFlat YoYGLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[19]GLP-1 & metabolic+30% searches
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Sermorelin if…

  • you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[18]

Consider Tirzepatide if…

  • you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[20]
  • you want large randomized weight-loss data (the SURMOUNT program): Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) with tirzepatide versus -3.1% with placebo.[19]
  • you are tested in sport and want to avoid a WADA-prohibited substance: WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin (check tirzepatide's own status separately)[4]

What they have in common

  • Sermorelin's only FDA record is Geref, listed with marketing status Discontinued[21]
Sermorelin is not FDA approved. Sermorelin is prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 12 of 14 fields where the two differ. PCAC vote, Jul 2026, Evidence strength are the same or both unknown.

FieldSermorelinTirzepatide
ClassGHRH analogGLP-1 / GIP dual agonist
Also called—tirz, tirze, Mounjaro, Zepbound
CategoryGrowth hormoneGLP-1 & metabolic
FDA statusCompounded by prescriptionFDA approved (Mounjaro, Zepbound)
WADAProhibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeNo published half-life foundPubMed search, 2 Oct 2026approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Human studies we summarised4 human (1 randomized or controlled) of 7 summarised24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 9 mg, 15 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg
US searches per month165,000 · Flat YoY1,220,000 · +30% searches
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Sermorelin and Tirzepatide together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Open the stack page
StackSermorelin + Tirzepatide, taken as separate injectionsStack page

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  6. 6Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  7. 7Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  8. 8Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  9. 9Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  10. 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  14. 14Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  15. 15Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  16. 16Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  17. 17PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  19. 19Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  20. 20ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  21. 21Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.